Effects of senescent cells on activity.

Slides:

Advertisements

Similar presentations

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Advertisements

Metabolic effects of TUG‐891 are reduced or absent in GPR120‐deficient mice Metabolic effects of TUG‐891 are reduced or absent in GPR120‐deficient mice.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

AZD7762 abrogated the G2 checkpoint in a novel hollow fiber assay.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Effects of SC144 on in vivo ovarian tumor.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Volume 21, Issue 11, Pages (December 2017)

Two distinct CXCR4 antagonists mobilize progenitor cells in mice by different mechanisms by Andia N. Redpath, Moïra François, Suet-Ping Wong, Dominique.

Treatment with AZD5363 reduces the proportion of proliferating vascular endothelial cells and following RT, the influx of CD11b+ bone marrow‐derived cells.

Deficiency in myeloid-resident NRP1 affects systemic metabolism.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Activity of MAC-321 (i. v. and p. o

Effect of MI-773 dosing on long-term efficacy.

Senescence-associated inflammation, bone marrow suppression, and cardiac dysfunction. Senescence-associated inflammation, bone marrow suppression, and.

Therapy-induced senescence of primary cells.

Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

A: Chemical structure of pterosin A

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

Cytokine changes in LPS-induced TNFα and spontaneous IL-6 production in whole-blood cultures. Cytokine changes in LPS-induced TNFα and spontaneous IL-6.

Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

GS87 demonstrates efficacy in a circulating AML mouse model system.

Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea and weight loss. Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

In vivo AraC treatment does not induce any consistent changes in CD34+/−CD38+/− phenotypes nor in quiescent leukemic cells but increases apoptotic cell.

Fig. 3. Human liver tissue seed graft function.

Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

GM-CSF is required for CA-MSC–induced tumor metastasis.

A, tumor growth studies in H1975 tumor–bearing mice.

Impairment of liver function upon treatment with 4D5MOCB-ETA.

Induction of liver NQO1 activity in juvenile female rats treated for 3 d (10 mg/kg qd SERMs or 0.1 mg/kg qd E2 or vehicle control). Induction of liver.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

C7R enhances adoptive T-cell immunotherapy against metastatic and intracranial malignancies.A and B, 1 × 106 CHLA-255 FFluc cells were injected i.v. into.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Metabolite profiling of DFMO-treated ApcMin mouse tumors.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

CDV potentiates the antitumor effect of ionizing radiation in mice intracerebrally implanted with human glioblastoma cells. CDV potentiates the antitumor.

TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development. TCR stimulation by agonistic mAb in vivo administration inhibits.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Serum IFNγ and immune responses following tecemotide/cisplatin combination treatment in a urethane-induced hMUC1.Tg lung cancer mouse model. Serum IFNγ.

PDL192 and inhibit the growth of xenograft tumors.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Effects of ZOL treatment on pulmonary metastases.

GCS-100 selectively kills KRAS-addicted lung tumors.

BV6 increases bone metastasis.

In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B cells harboring Jak3V670A. In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B.

WEE1 inhibition followed by TRAIL treatment results in apoptotic cell death in MB231 cells. WEE1 inhibition followed by TRAIL treatment results in apoptotic.

Treatment with octyl-D-2-HG and octyl-L-2-HG reduces MIR148A expression. Treatment with octyl-D-2-HG and octyl-L-2-HG reduces MIR148A expression. A, Treatment.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

Effects of senescent cells on activity. Effects of senescent cells on activity. Control-treated or Doxo-treated (10 mg/kg) p16-3MR female mice were treated with vehicle (PBS) or 25 mg/kg of GCV for 5 days (daily i.p. injections). A, Mice were single-housed in metabolic cages and monitored for 4 consecutive days. Data are the average of 4 day and night cycles and show the percentage of time spent on the running wheel. N = 8. B, Running distance in meters, calculated from the number of revolutions of the running wheel, during the nocturnal cycles (average of 4). N = 8. C, Mice were single-housed in standard cages equipped with running wheels. The number of revolutions was determined before Doxo treatment and 12 days after Doxo treatment. For each mouse, values are from an average of 3 consecutive nights. The graph shows the ratio between the post- and pretreatment running distance, expressed as a percentage. N = 10. D, Mice described in C were monitored for how long they were capable of grasping a reversed cage grid. For each mouse, values are an average of 5 trials. The graph shows the ratio between the post- and pretreatment grasping time, expressed as a percentage. N = 10. E, Food intake of the mice described in A was measured during the night cycles. Data are means ± SEMs. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Marco Demaria et al. Cancer Discov 2017;7:165-176 ©2017 by American Association for Cancer Research